Despite triage systems in place to exclude patients with coronavirus disease 2019 (COVID-19), viral material was found on ophthalmology examination room surfaces at one center, though the infectivity of the samples was unknown.
Despite triage systems in place to exclude patients with coronavirus disease 2019 (COVID-19), viral material was found on ophthalmology examination room surfaces at one center, though the infectivity of the samples was unknown. Results from the small quality improvement study were published in JAMA Ophthalmology.1
COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped, single-stranded RNA virus, primarily transmitted through person-to-person contact. However, several studies have suggested the virus can be spread via contaminated surfaces.
One study of cruise ship outbreaks of SARS-CoV-2 reported “viral RNA was identified on the surfaces of cabins up to 17 days after patient disembarkation,” authors wrote.
To determine whether ophthalmologists risk encountering asymptomatic individuals with COVID-19 when maintaining elective examinations, researchers collected samples from 1 examination room in İzmir Tepecik Training and Research Hospital, İzmir, Turkey, one week after the first confirmed COVID-19 case in the country.
After the outbreak’s inception on March 11, 2020, patients and health care workers in the Turkish clinic were triaged by the pandemic management committee. Any patient and their companions with foreign travel histories to then-affected areas (China, Italy, and Iran) or contact with any person with a confirmed or suspected case were excluded from elective examinations. Patients with fever, coughing, or general illness were also excluded while patients showing no symptoms were examined. Medical personnel with no symptoms were not screened for COVID-19.
A plastic slit lamp breath shield was used as a physical barrier in the examination room. “The room was cleaned with hydrogen peroxide, 3%, after the last examination and had no visitors for approximately 18 hours after cleaning,” researchers wrote. “No room cleaning was done between patients, but chin and forehead rests were wiped with isopropyl alcohol, 70%, between the patients.”
Fourteen samples were taken from the biomicroscope stage, slit lamp shield, phoropter, tonometer, and door handles before and after patients visited on March 20, 2020, and were tested by real-time polymerase chain reaction (RT PCR).
Of the 29 patients who went to the hospital for an eye exam, 7 were directed for COVID-19 tests following triage and did not enter the examination room. A total of 22 patients went to the exam room with 9 companions and 1 healthcare professional (who was not symptomatic). Mean examination time was around 9 minutes.
RT PCR tests revealed:
“This study provided objective data about the potential for patients who are asymptomatic, those accompanying them, or health care personnel in an eye examination room to leave viral material on the surfaces tested,” researchers wrote.
Because RT PCR establishes only the presence of viral material and provides no information about infectivity, virulence, viability, or viral load, authors cautioned the study’s outcomes cannot determine the potential infection risk of encountering an individual carrying the virus asymptomatically during a routine eye examination.
To partially address this issue and to reduce COVID-19 exposure among at-risk patients visiting ophthalmology clinics,2 additional researchers recently developed a flexible and scalable scoring algorithm for patients with glaucoma aimed at triaging those seeking ophthalmologic care.
Patients with chronic ocular diseases, such as glaucoma, risk experiencing irreversible visual acuity or visual field loss from disease progression if they are unable to receive timely medical care, the researchers explained. “Yet a disproportionately large number of patients with glaucoma are also of older age and have medical comorbidities that predispose them to morbidity and mortality from COVID-19.”
Specifically, the algorithm’s success demonstrates how researchers can leverage big data to triage ophthalmic clinic appointments, balancing the glaucoma progression risk against the morbidity risk from COVID-19 exposure.
References:
1. Aytoğan H, Ayintap E, and Yılmaz NO. Detection of coronavirus disease 2019 viral material on environmental surfaces of an ophthalmology examination room. JAMA Ophthalmol. Published online August 3, 2020. doi:10.1001/jamaophthalmol.2020.3154
2. Bommakanti NK, Zhou Y, Ehrlich JR, et al. Application of the sigh outcomes research collaborative ophthalmology data repository for triaging patients with glaucoma and clinic appointments during pandemics such as COIVD-19. JAMA Ophthalmol. Published online July 17, 2020. doi:10.1001/jamaophthalmol.2020.2974
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
2 Commerce Drive
Cranbury, NJ 08512